Ligand proposes $400M convertible notes due 2030; up to $60M greenshoe

LIGAND PHARMACEUTICALS INC

Offering $400M aggregate principal amount of convertible senior notes due Oct 1, 2030 to QIBs.
Initial purchasers have 13-day option to buy up to an additional $60M of notes.
Up to $30M of net proceeds used to repurchase common stock from note purchasers.
Remaining net proceeds for general corporate purposes, including potential acquisitions.
Convertible note hedge and warrant transactions entered to manage dilution and offset cash payments.

item 1.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.